[Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening].
Jérôme
J
Desramé
Christian
C
Duvic
Dominique
D
Béchade
Christian
C
Bredin
J J
JJ
Raynaud
G
G
Defuentes
Louis-Marie
LM
Dourthe
Jean-Pierre
JP
Algayres
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D008403:Mass Screening; D008654:Mesothelioma / Q000188:drug therapy; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine